Abstract: A method of manufacturing a metal fabric or membrane, the method comprises providing an ink comprising a plurality of semiconductor particles disposed in a first solvent. The method comprises applying the ink to a fabric or membrane to obtain a fabric or membrane comprising a plurality of semiconductor particles. Finally, the method comprises contacting the fabric or membrane comprising the plurality of semiconductor particles with a deposition solution comprising a second solvent, an autocatalytic agent, and metal cations to thereby cause a reaction to occur such that the metal cations are reduced and at least partially displace the semiconductor particles, to thereby provide a metal fabric or membrane.

Abstract: A neck pillow for supporting the head of a user comprises left, right, and rear portions so as to be generally U-shaped. The neck pillow may include an inner frame which may be made of a material more rigid and denser than an outer material of the pillow so as to provide support. The left and right portions may include a chin support or protrusion so as to increase user comfort. Pillows according to the present disclosure may also include anchor points on each side for adjustment of the degree to which a closure mechanism attached to a connector such as a drawstring can be tightened. A closure mechanism which may be attached to the drawstring portions may include internal components that can prevent or make more difficult disconnection via horizontal force, and may also include magnets for connection of the left and right sides thereof.

Abstract: A fingernail polishing assembly for sanding fingernails and toenails includes a vibration unit that may be manipulated. A sander is removably coupled to the vibration unit. The sander may frictionally engage a nail when the vibration unit is manipulated. Thus, the sander may sand the nail.

Abstract: A neck pillow for supporting the head of a user comprises left, right, and rear portions so as to be generally U-shaped. The neck pillow may include an inner frame which may be made of a material more rigid and denser than an outer material of the pillow so as to provide support. The left and right portions may include a chin support or protrusion so as to increase user comfort. Pillows according to the present disclosure may also include anchor points on each side for adjustment of the degree to which a closure mechanism attached to a connector such as a drawstring can be tightened. A closure mechanism which may be attached to the drawstring portions may include internal components that can prevent or make more difficult disconnection via horizontal force, and may also include magnets for connection of the left and right sides thereof.

Abstract: A software enabled system employable for medical or other product authentication is provided. The system enabled by software running on a computer with electronic memory and connected databases is adapted for users having a local computing device to input captured product characteristic information which is compared with authenticating characteristics in databases to generate an authenticity rating for each product. Such captured product characteristics may include, for instance, digital photos, keyboard input, voice input, or digital values generated from computer engaged sensors for weight, color, density, or other discernable product characteristics which may be digitally uploaded and employed in a comparison to known authenticating characteristics. Certain product characteristics may be more heavily rated in deriving each authenticity rating which is communicated to the user.

Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Abstract: The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Abstract: The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.